tradingkey.logo

Gan & Lee Pharmaceuticals Presented Multiple Results In Novel Diabetes Therapies At The American Diabetes Association's 85Th Scientific Sessions

ReutersJun 21, 2025 9:53 AM

- Gan & Lee Pharmaceuticals 603087.SS:

  • GAN & LEE PHARMACEUTICALS PRESENTED MULTIPLE RESULTS IN NOVEL DIABETES THERAPIES AT THE AMERICAN DIABETES ASSOCIATION'S 85TH SCIENTIFIC SESSIONS

  • GAN & LEE PHARMACEUTICALS - PHASE 2A TRIAL SHOWS BOFANGLUTIDE INJECTION REDUCES HBA1C IN T2DM PATIENTS

  • GAN & LEE PHARMACEUTICALS - PHASE 2B TRIAL SHOWS BOFANGLUTIDE SUPERIOR TO SEMAGLUTIDE IN HBA1C REDUCTION

  • GAN & LEE PHARMACEUTICALS - PHASE 2 TRIAL SHOWS GZR4 INJECTION SUPERIOR TO TRESIBA IN HBA1C REDUCTION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI